Microwave ablation determines similar survival outcomes as compared to radiofrequency ablation for the treatment of hepatocellular carcinoma

Khan A 1 , Mostowy M 2 , Owusu M 3 , Mutambanengwe M 4 , Habimana S 5 , Bence S 6 Show all authors , Facciorusso A 7

Affiliations 

  • 1 Department of Pharmaceutics, School of Pharmaceutical Sciences, Universiti Sains Malaysia
  • 2 Orthopedic and Trauma Department, Veteran's Memorial Teaching Hospital in Lodz, Medical University of Lodz, Lodz, Poland
  • 3 College of Health Sciences, Department of Medical Diagnostic, Kumasi Centre for Collaborative Research in Tropical Medicine, Kumasi, Ghana
  • 4 University of Zimbabwe, Harare, Zimbabwe
  • 5 University of Rwanda, Kigali, Rwanda
  • 6 Department of Obstetrics and Clinic for Production Animal, University of Veterinary Medicine, Budapest, Hungary
  • 7 Department of Medical Sciences, Gastroenterology Unit, University of Foggia, Foggia, Italy
Expert Rev Gastroenterol Hepatol, 2021 Jul;15(7):829-833.
PMID: 33356655 DOI: 10.1080/17474124.2021.1869939

Abstract

OBJECTIVES: It is still unclear whether microwave ablation (MWA) outperforms radiofrequency ablation (RFA) in the treatment of hepatocellular carcinoma (HCC). Aim of this manuscript is to compare the two treatments through a meta-analysis of randomized-controlled trials (rcts).

METHODS: Computerized bibliographic search was performed on main databases through August 2020. The primary outcome was the complete response rate, with survival rate, disease-free survival rate, and adverse event rate as secondary outcomes. Results were expressed in terms of risk ratio (RR) and 95% confidence interval (CI).

RESULTS: Seven rcts enrolling 1143 patients were included. Rates of complete response were similar (RR 1.01, 95% CI 0.99-1.02); likewise, survival rates were constantly similar, with rrs ranging from 1.05 (0.96-1.15) at 1-year to 0.91 (0.81-1.03) at 5-year. Disease-free survival at 1-, 2-, and 3-year was similar between the two groups with RR 1.00 (0.96-1.04), 0.94 (0.84-1.06), and 1.06 (0.93-1.21), respectively. On the other hand, RR for disease-free survival at 5-year was significantly in favor of MWA (3.66, 1.32-42.27). Adverse event rate was similar between the two treatments (RR 1.06, 0.48-2.34), with bleeding and hematoma as most frequent complications.

CONCLUSIONS: MWA seems to determine similar outcomes as compared to RFA.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications